Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors

Details Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors

2011-03-01

2011-03-01

Morris, Patricia L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S344000, C514S348000, C514S252180, C546S288000, C546S296000, C546S297000, C544S360000

Reexamination Certificate

active

07897624

ABSTRACT:
This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.

REFERENCES:
patent: 5596008 (1997-01-01), Lee et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 6235764 (2001-05-01), Larson et al.
patent: 6495582 (2002-12-01), Hale et al.
patent: 6511993 (2003-01-01), Dack et al.
patent: 6548526 (2003-04-01), Larson et al.
patent: 6649640 (2003-11-01), Hale et al.
patent: 6989451 (2006-01-01), Zhang et al.
patent: 2003/0149015 (2003-08-01), Barrett et al.
patent: 2004/0029898 (2004-02-01), Boyle et al.
patent: 2004/0039037 (2004-02-01), Zhang et al.
patent: 2004/0152691 (2004-08-01), Lippa et al.
patent: 2005/0143438 (2005-06-01), Wallace et al.
patent: 2007/0244164 (2007-10-01), Yan et al.
patent: 2008/0058340 (2008-03-01), Maderna et al.
patent: 0239362 (1987-09-01), None
patent: 0606046 (1994-07-01), None
patent: 0780386 (1997-06-01), None
patent: 0818442 (1999-01-01), None
patent: 0931788 (1999-08-01), None
patent: 1004578 (2000-05-01), None
patent: 1181017 (2002-02-01), None
patent: WO-90-05719 (1990-05-01), None
patent: WO-96-27583 (1996-09-01), None
patent: WO-96-33172 (1996-10-01), None
patent: WO-98-03516 (1998-01-01), None
patent: WO-98-07697 (1998-02-01), None
patent: WO-98-30566 (1998-07-01), None
patent: WO-98-33768 (1998-08-01), None
patent: WO-98-34915 (1998-08-01), None
patent: WO-98-34918 (1998-08-01), None
patent: WO-99-07675 (1999-02-01), None
patent: WO-99-29667 (1999-06-01), None
patent: WO-99-52889 (1999-10-01), None
patent: WO-99-52910 (1999-10-01), None
patent: WO-03-043985 (2003-05-01), None
Balant et al., “Metabolic Considerations, etc.,” in Manfred ed., Burger's Medicinal Chemistry and Drug Discovery, 5th ed. vol. 1:Prinicples and Practice, John Wiley & Sons, Inc., 1995.
Vippagunta et al., “Crystalline Solids”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Jain et al., “Polymorphism in Pharmacy”, Indian Drugs, 1986, 23(6), 315-329.
Guillory (in Brittain ed.), “Polymorphism, etc.,” NY: Marcel Dekker, Inc., 1999, 1-2, 183-226.
Silverman, R.B., The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, 1992, pp. 4-51.
Berge et al., “Pharmaceutical salts,” J. Pharm. Sci. 66(1): 1-19, 1977.
Buchwald et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,” Surgery 88(4): 507-16, 1980.
Bundgaard, H. Chapter 5: Design and application of prodrugs. A Textbook of Drug Design and Development. Krosgaard-Larsen, et al., eds., pp. 113-191, 1991.
Bundgaard, H., “Means to enhance penetration: Prodrugs as a means to improve the delivery of peptide drugs,” Advanced Drug Delivery Reviews 8: 1-38, 1992.
Fedorak et al., “A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis,” Am J Physiol 269(2 Pt 1): G210-8, 1995.
Fleisher et al., “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs,” Advanced Drug Delivery Reviews 19(2): 115-30, 1996.
Furniss et al., ed., Vogel's Textbook of Practical Organic Chemistry, 5th Ed. Suppl. (Longman Scientific and Technical Ltd, Essex, UK) pp. 809-816, 1991.
Goodson, J. Dental applications. Medical Applications of Controlled Release, vol. 2, Applications and Evaluations. Langer, et al., eds. (CRC Press, Boca Raton, FL) pp. 115-138, 1984.
Heller, A., “Electrical wiring of redox enzymes,” Acc Chem Res 23(5): 128-34, 1990.
Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed Chromatogr. 1992; 6(6): 1992.
Langer, R., “New methods of drug delivery,” Science 249(4976): 1527-33, 1990.
Larsen, et al., “Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivative, N-sulfonylamidines, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives,” Int J Pharmaceutics 37(1-2): 87-95, 1987.
Larsen et al., “Prodrug forms for the sulfonamide group. II. Water-soluble amino acid derivatives of N-methylsulfonamides as possible prodrugs,” Int J Pharmaceutics 47(1-3): 103-10, 1988.
Mcleod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterology 106(2): 405-13, 1994.
Robinson et al., “Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH group,” J Med Chem 39(1): 10-8, 1996.
Saudek et al., “A preliminary trial of the programmable implantable medication system for insulin delivery,” N Engl J Med 321(9): 574-9, 1989.
Saulnier et al., “An efficient method for the synthesis of guanidino prodrugs,” Bioorganic & Medicinal Chemistry Letters 4(16): 1985-90, 1994.
Sefton, M., “Implantable pumps,” Crit Rev Biomed Eng 14(3): 201-40, 1987.
Sinkula et al., “Rationale for design of biologically reversible drug derivatives: prodrugs,” J Pharm Sci 64(2): 181-210, 1975.
Treat et al., “Liposome encapsulated doxorubicin: Preliminary results of phase I and phase II trials,” Liposomes in the Therapy of Infectious Diseases and Cancer. Lopez-Bernstein, et al., eds. (Alan R. Liss, New York) pp. 353-365, 1989.
Varaprasad et al., “Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors,” Bioorg Med Chem Let 16(15):3975-3980, 2006.
Widder et al., ed., Methods in Enzymology (Academic Press, New York) vol. 112, pp. 309-396, 1985.
PCT/US07/66894 Search Report dated Feb. 15, 2008.

Affiliated with

Also associated with

Rating

Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2764729